Non-invasive assessment of coronary microvascular dysfunction using multimodality imaging is essential for risk stratification of heart failure and sudden cardiac death in hypertrophic cardiomyopathy.
Non-invasive assessment of coronary microvascular dysfunction using multimodality imaging is crucial for risk stratification of heart failure and sudden cardiac death in patients with hypertrophic cardiomyopathy.
Myocardial ischemia is an established pathophysiological feature of hypertrophic cardiomyopathy (HCM) that impacts various clinical features, including heart failure (HF) and sudden cardiac death (SCD). The major determinant of myocardial ischemia in HCM is coronary microvascular dysfunction (CMD) in the absence of epicardial coronary artery abnormalities. Despite the impossibility to directly visualize microcirculation in vivo, a multimodality approach can allow a detailed assessment of microvascular dysfunction and ischemia. Accordingly, the non-invasive assessment of CMD using transthoracic Doppler echocardiography, positron emission tomography, and cardiac magnetic resonance should now be considered mandatory in any HCM patient. Noteworthy, a complete diagnostic work-up for myocardial ischemia plays a major role in the approach of the patients with HCM and their risk stratification. Chronic and recurrent episodes of ischemia can contribute to fibrosis, culminating in LV remodeling and HF. Ischemia can potentially constitute an arrhythmic substrate and might prove to have an added value in risk stratification for SCD. Accordingly, strategies for the early diagnosis of CMD should now be considered an important challenge for the scientific community.
Pelliccia et al. (Fri,) conducted a review in Hypertrophic Cardiomyopathy. Non-invasive assessment of coronary microvascular dysfunction was evaluated. Non-invasive assessment of coronary microvascular dysfunction using multimodality imaging is essential for risk stratification of heart failure and sudden cardiac death in hypertrophic cardiomyopathy.